STW:PA:PA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 188.06

Change

-10.14 (-5.12)%

Market Cap

USD 0.72B

Volume

2.14K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-07 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

+0.45 (+1.05%)

USD 55.57B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

+4.05 (+0.85%)

USD 13.81B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

+2.54 (+0.74%)

USD 12.91B
WRD:PA HSBC MSCI World UCITS ETF

+0.39 (+1.24%)

USD 11.43B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

+3.73 (+1.58%)

USD 9.42B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

+3.70 (+0.91%)

USD 8.68B
WLD:PA Lyxor UCITS MSCI World D-EUR

+2.94 (+0.95%)

USD 7.98B
HHH:PA HSBC S&P 500 UCITS ETF

+0.42 (+0.88%)

USD 7.67B
HSTE:PA HSBC ETFS PLC - HSBC Hang Seng..

-0.09 (-1.44%)

USD 6.16B
SPY4:PA SSgA SPDR S&P 400 US Mid Cap

+1.06 (+1.43%)

USD 5.54B

ETFs Containing STW:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.23% 45% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.23% 44% F 42% F
Trailing 12 Months  
Capital Gain -11.46% 17% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.46% 16% F 36% F
Trailing 5 Years  
Capital Gain 25.69% 35% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.69% 33% F 45% F
Average Annual (5 Year Horizon)  
Capital Gain 9.34% 56% F 64% D
Dividend Return 9.34% 55% F 79% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.91% 71% C- 92% A
Risk Adjusted Return 118.10% 92% A 99% N/A
Market Capitalization 0.72B 72% C 74% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike